• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

AccessHope Secures $33M to Expand Cancer Care Expertise

by Fred Pennic 04/22/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
AccessHope Secures $33M to Expand Cancer Care Expertise

What You Should Know: 

– AccessHope, a company revolutionizing how cancer patients receive cutting-edge treatment plans secures $33M in a Series B funding round led by City of Hope, a prominent cancer research and treatment organization.  

– The company plans to use the investment to fuel AccessHope’s next phase of growth as a standalone company.

New CEO Bradley Kreick Takes the Helm

To spearhead this growth trajectory, AccessHope has appointed seasoned healthcare veteran Bradley Kreick as its new CEO.  Kreick boasts 30 years of experience leading companies through periods of significant growth, ideally positioned to guide AccessHope’s commercial expansion.  Mark Stadler, AccessHope’s former CEO, will transition to the role of Chief Growth Officer, focusing on expanding cancer care benefits within health plans, Medicare, and government programs.

Cancer Collaboration Network

AccessHope’s success hinges on its unique collaboration with some of the nation’s leading National Cancer Institute (NCI)-Designated Comprehensive Cancer Centers, including City of Hope, Dana-Farber Cancer Institute, and Johns Hopkins Medicine.  Through these partnerships, AccessHope grants its members access to a network of over 350 top oncologists, encompassing all cancer types and stages.

Delivering Expertise Where Patients Need It Most

AccessHope’s innovative approach empowers local oncologists by providing them with access to the latest cancer treatment insights from leading cancer centers. This collaboration ensures patients benefit from cutting-edge knowledge without leaving their local healthcare providers.  AccessHope currently offers its services to over seven million members through partnerships with more than 400 employers, including over 60 Fortune 500 companies.

“AccessHope was founded with the mission of bringing cutting-edge cancer care knowledge to the places and people who need it most. Today, we are proud to serve nearly seven million members through more than 400 employers, including over 60 Fortune 500 companies and two of the nation’s largest health plans,” said Harlan Levine, M.D., chair of the AccessHope board and president, Health Innovation and Policy at City of Hope. “As demand for personalized cancer care benefits offered by AccessHope continues to grow, it is an ideal time for City of Hope to provide strategic funding and the autonomy for it to operate as a stand-alone company. This move will enable AccessHope to accelerate innovation and expand into new markets and regions, while continuing to extend access to the best cancer treatment expertise regardless of who you are and where you live.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Detection, Oncology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |